Adam Besvinick

    Adam Besvinick is an early-stage investor who backs pre-seed and seed founders. In this episode, we discuss his framework for building conviction, evaluating defensibility in AI, and navigating enterprise health systems. We also dig into fundraising dynamics and how founders should think about capital strategy across early rounds.

    What did Adam Besvinick teach us?

    1. 01

      A pass from another investor is not a signal about a company's quality. At pre-seed, there is so much uncertainty that even top investors are frequently wrong.

    2. 02

      Building software has gotten easier, so distribution and deep industry relationships are the real defensible edge. Founders who already have networks of buyers in complex fields like healthcare have a massive advantage on day zero.

    3. 03

      Scraping public data does not create a defensible business. Strong companies build compounding data network effects, where each new customer improves the product or generates valuable data exhaust.

    4. 04

      Selling data to frontier AI labs can help reduce burn, but relying entirely on them is dangerous. These labs can and will enter your market unexpectedly.

    5. 05

      Epic dominates large health systems, but specialty care relies on a fragmented ecosystem of smaller EMRs. This fragmentation creates real opportunities for startups, especially since Epic has been slow to release AI-native features.

    6. 06

      Founders should keep early rounds disciplined, but raise aggressively at seed. The bar for a Series A is higher than ever, making extra capital worth the additional dilution.

    Lessons summarized from Sathvik Bilakanti's Substack write-up, not verbatim quotes.